4971 results for "Psychedelics"
Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.
Frontiers in psychiatry – January 01, 2025
Summary
Americans who use psychedelic mushrooms and other psychedelics reported higher rates of anxiety and depression compared to non-users, according to recent population data. Among 6,869 adults surveyed, those who used psilocybin mushrooms alone or combined with other psychedelics showed lower mental health scores, even after accounting for pre-existing conditions. These findings highlight important patterns in mental health among psychedelic users.
Abstract
Few population-based studies have examined associations between psychedelic use and mental health outcomes. This work describes characteristics of ...
Psychedelic‐assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports
Pharmacology Research & Perspectives – February 02, 2021
Summary
Remarkably, some debilitating neurological symptoms, once termed 'hysteria' or conversion disorder, may find new hope. A theoretical review explores how psychedelic-assisted therapy could treat these conditions, often rooted in psychosomatic medicine. Examining prior reports and neuroimaging suggests hallucinogens, by impacting serotonin receptors, positively influence these disorders, offering a promising path for patients.
Abstract
Abstract Functional neurological disorders (FNDs), which are sometimes also referred to as psychogenic neurological disorders or conversion disorde...
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.
Molecular psychiatry – July 07, 2025
Summary
Remarkably, rapid-acting compounds can relieve severe depressive disorder symptoms in mere hours. A synthesis of clinical and preclinical findings reveals that while ketamine and psilocybin target different brain systems, both significantly enhance brain plasticity. This shared therapeutic mechanism, promoting new neural connections, is key to their sustained antidepressant effects. Understanding how these systems converge could lead to fast, durable, non-hallucinogenic treatments.
Abstract
Major depressive disorder is a debilitating condition, with many patients unresponsive to conventional monoaminergic antidepressants. Rapid-acting ...
Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.
Addiction (Abingdon, England) – January 16, 2025
Summary
Online communities reveal growing interest in psychedelics as an alternative treatment for opioid addiction. Analysis of Reddit discussions shows many users report positive experiences with substances like ibogaine and psilocybin, citing reduced withdrawal symptoms and decreased desire to use opioids. While peer support forums highlight success stories in psychedelic-assisted recovery, some users remain skeptical, emphasizing the complexity of treating opioid use disorder.
Abstract
The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing need...
Is Personal Experience Essential for Effective Psychedelic Therapists?: The Challenges of Small, Accumulating Therapist Effects.
Psychedelic Med (New Rochelle) – September 04, 2024
Summary
Surprisingly, a therapist's personal encounter with psychedelics may not be the most critical factor for patient success in psychedelic-assisted therapy. This inquiry examined whether a therapist's own experience significantly influences patient outcomes, considering subtle, accumulating effects. The findings suggest that while personal experience might play a role, it's not essential. Instead, a therapist's core skills and professional training are paramount for achieving positive results, underscoring the value of robust therapeutic competence.
Abstract
Is Personal Experience Essential for Effective Psychedelic Therapists?: The Challenges of Small, Accumulating Therapist Effects.
Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.
Frontiers in psychology – January 01, 2023
Summary
Leaders who practice mindfulness meditation or have meaningful psychedelic experiences report significant improvements in their leadership abilities. A large study of 3,150 managers found that both practices enhanced leadership qualities in distinct ways. Meditation boosted focus, patience, and stress management, while psychedelics fostered creativity, empathy, and less hierarchical thinking. Those with more meditation hours or profound psychedelic insights were twice as likely to report positive leadership changes.
Abstract
Previous research suggests that mindfulness meditation and psychedelic substances show promise as mental health interventions, but relatively littl...
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy
CORE – January 01, 2021
Summary
Psychedelic-assisted therapy shows remarkable potential in treating addiction, combining traditional psychotherapy with carefully controlled psychedelic experiences. Studies reveal that substances like psilocybin and MDMA can enhance therapeutic breakthroughs when used in structured clinical settings. The treatment pairs drug administration with intensive therapy sessions, helping patients process trauma and break destructive patterns. Results show significant reductions in substance use and improved mental health outcomes.
Abstract
Purpose of Review: The use of psychedelics in a therapeutical setting has been reported for the treatment of various diagnoses in recent years. How...
Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices.
British journal of clinical pharmacology – December 01, 2024
Summary
Psychedelic compounds like dimethyltryptamine (DMT) and ayahuasca are showing promise in treating chronic pain and mental health conditions. Anesthesiologists play a crucial role in administering these substances safely, monitoring patients, and managing potential psychedelic toxicity. Research reveals these treatments can be effective when properly supervised, with protocols focusing on careful screening, dosing, and medical oversight.
Abstract
Recent years have witnessed an unprecedented increase in the search for the use of psychedelics in improving physical and mental health. Anaesthesi...
Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2023
Summary
Healthcare providers who prescribe psychiatric medications reported significant improvements in their own mental wellness after personal psychedelic use. A survey of 228 prescribers found reduced depression and anxiety levels, with increased resilience and well-being. Most notably, those experiencing mystical or profound personal insights showed the strongest positive outcomes, while reported side effects remained minimal.
Abstract
Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are fa...
The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.
American journal of psychotherapy – May 06, 2025
Summary
Physical touch during psychedelic therapy sessions can play a vital role in patient care, according to healthcare practitioners. While 70% of surveyed professionals view therapeutic touch as crucial during psilocybin and other psychedelic treatments, clear ethical boundaries are essential. Most support gentle contact like hand-holding, with explicit consent required. This balanced approach helps create a safe, supportive environment while maintaining professional standards.
Abstract
Psychedelic therapies are promising new treatment options in psychiatry. Including the use of physical touch as part of treatment is an area of deb...
Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal
CrossRef
Summary
Our early relationships profoundly shape how we connect with others and the divine. This framework proposes that psychedelics could help relax rigid mental patterns formed by these foundational experiences. It suggests an individual's attachment security influences their psychedelic journey, and that effective psychedelic therapy may actually boost this security. The process involves fostering a deeper sense of connection and easing worries, enhancing treatment benefits.
Abstract
In this paper, we set an agenda for a psychedelic science of spirituality and religion, based on a synthesis of attachment theory with the Relaxed ...
Psychedelic‐assisted therapy considered ‘breakthrough’ treatment for PTSD
Mental Health Weekly – May 17, 2021
Summary
A groundbreaking therapy is showing profound success in alleviating severe, chronic PTSD. This innovative approach, utilizing psychedelic-assisted sessions, aims to provide lasting relief where traditional treatments often fall short. Promising findings indicate significant symptom reduction, offering new hope. This advancement could pave the way for FDA approval, marking a major step forward in mental health care.
Abstract
New research involving the use of psychedelic‐assisted therapy is showing promise and significant implications for patients with severe, chronic po...
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs.
Expert review of clinical pharmacology – June 11, 2025
Summary
Breakthrough research reveals psychedelic compounds like psilocybin and LSD can rapidly alleviate depression through multiple interconnected pathways. Unlike traditional antidepressants, these substances work by simultaneously affecting brain chemistry, psychological patterns, and consciousness. The therapeutic effects emerge from a complex interplay of biological changes and meaningful experiences during psychedelic-assisted therapy.
Abstract
Psychedelic compounds are emerging treatments for depression, capable of producing rapid and lasting symptom reduction after 1-2 administrations in...
Subjective Effects of Psychedelics Are the Plausible Mechanism of Psychedelic Moral Enhancement Rather than a Risk. Comment on Tang, B.L. Psychedelics for Moral Bioenhancement in Healthy Individuals—A Violation of the Non-Maleficence Principle? Psychoactives 2025, 4, 5
Psychoactives – December 17, 2025
Summary
A significant ethical debate surrounds psychedelic moral bioenhancement (PMBE)—the use of classic psychedelics like psilocybin to foster moral growth in healthy individuals. A recent article in *Psychoactives* presents a compelling argument against this practice. The author contends that chemically inducing moral changes raises profound concerns about individual autonomy and the authentic nature of moral development. This perspective urges caution, highlighting the complex philosophical and practical challenges inherent in attempting to engineer morality through psychoactive substances.
Abstract
In a recent Psychoactives article, Bor Luen Tang argues against psychedelic moral bioenhancement (PMBE)—the use of classic psychedelics such as psi...
A predictive coding approach to psychedelic virtual-induced hallucinations and creative cognition in aging
Frontiers in Human Neuroscience – July 07, 2023
Summary
Virtual Reality (VR) offers a safe avenue to explore psychedelic-like effects, significantly boosting Cognitive Flexibility crucial for Creativity. This Cognitive Psychology approach suggests VR-induced changes in Perception and sensory input—relevant to Olfactory and Sensory Function Studies—can optimize how our Cognition balances expectations. Enhancing Cognitive Flexibility and Executive functions through such Psychedelics and Drug Studies-inspired methods could be vital for maintaining robust brain health, particularly in aging, preventing declines seen in conditions like Mild Cognitive Impairment, and potentially enriching Aesthetic Perception and Analysis.
Abstract
Recent research has investigated the potential of psychedelic substances in treating various neurological and psychiatric disorders. In particular,...
Adverse Events Should Not Be Surprising in Psychedelic Research.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2025
Summary
As psychedelics gain momentum in mental health treatment, balanced science communication is crucial. While these compounds show promise, adverse events in clinical trials range from mild anxiety to rare but serious psychological reactions. Medical professionals are working to better understand and communicate both benefits and risks, ensuring patients can make informed decisions. Responsible use requires careful screening and monitoring.
Abstract
Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In...
Classic psychedelics and the treatment for alcoholism.
Progress in neuro-psychopharmacology & biological psychiatry – December 20, 2024
Summary
A single dose of classic psychedelics can significantly reduce alcohol dependence, offering hope for those struggling with alcohol use disorder. These substances work by rewiring neural pathways in the brain, helping patients break free from destructive drinking patterns. Clinical trials show remarkable success rates, with many participants maintaining sobriety after treatment. Unlike conventional therapies, psychedelic-assisted treatment appears to address the root causes of dependence, rather than just managing symptoms.
Abstract
Alcohol is a harmful drug, and reducing its consumption is a significant challenge for users. Furthermore, alcohol dependence is often treatment-re...
In Becoming. Instability of Psychedelic Substances
Etnografia Polska – December 22, 2022
Summary
A key insight reveals a substance's identity as 'medicine' or 'illicit drug' isn't fixed. Research, aligned with the 'ontological turn,' uses ethnographic examples from the 'psychedelic renaissance' to show how embodied user practices and scientific knowledge production practices destabilize rigid drug scheduling. This challenges traditional views on drug use and abuse, fostering positive perspectives for areas like psychedelic-assisted therapy.
Abstract
Psychoactive substances are subject to law control, imposed through the system of medical prescription or legal prohibition, with legal penalties f...
The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.
Psychiatry research – June 01, 2025
Summary
Psychedelic compounds show promising potential in treating opioid use disorder, offering hope beyond traditional treatments. Studies reveal that substances like ketamine and ibogaine can significantly reduce withdrawal symptoms and cravings. While classic psychedelics like psilocybin and LSD demonstrate potential, the strongest evidence currently supports ketamine's effectiveness. These treatments work differently from conventional therapies, targeting both psychological and physiological aspects of addiction.
Abstract
Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United Sta...
Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being.
Journal of psychopharmacology (Oxford, England) – October 01, 2024
Summary
Intense positive experiences during psychedelic sessions may be linked to specific patterns in our body's autonomic nervous system. Research shows that when both branches of this system are simultaneously active during DMT sessions, participants report more meaningful spiritual insights and show improved well-being weeks later. Heart rate patterns before treatment also predicted how profound the experience would be.
Abstract
Non-ordinary states of consciousness induced by psychedelics can be accompanied by so-called "peak experiences," characterized at the emotional lev...
Australian psychologists' attitudes towards psychedelic‐assisted therapy and training following a world‐first drug down‐scheduling
Drug and Alcohol Review – November 05, 2024
Summary
Australian psychologists largely embrace psychedelic-assisted therapy for mental health, viewing it as a promising psychological intervention. A nonprobability snowball sampling of 20 psychologists revealed most had positive attitudes towards these compounds, often products of chemical synthesis and alkaloids like psilocybin. However, limited knowledge and concerns about efficacy and adverse experiences were noted. This highlights the critical need for comprehensive medical education and training to ensure competence in this evolving area of clinical psychology and applied psychology, integrating diverse academic research themes from psychedelics and drug studies.
Abstract
Abstract Introduction This study explores the attitudes of psychologists towards psychedelics and psychedelic‐assisted therapy (PAT) following the ...
Expectancy Effects in Psychedelic Trials.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Positive expectations may significantly influence outcomes in psychedelic therapy, even with microdosing. When participants believe they'll benefit, they often do - highlighting the complex relationship between mind and medicine. Researchers found that proper trial design and blinding procedures are crucial, as the placebo effect can be particularly strong with psychedelics. This understanding helps optimize therapeutic benefits while improving future treatment protocols.
Abstract
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconside...
History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).
Journal of psychoactive drugs – January 01, 2014
Summary
Born from a 1980s vision that psychedelics could aid humanity, one organization pioneered rigorous MDMA-assisted therapy for PTSD. They achieved positive results in the first double-blind, placebo-controlled trials, with FDA approval planned. Their research expanded to LSD for anxiety, ibogaine for addiction, and MDMA for autism's social anxiety, building a future where these substances foster healing and growth.
Abstract
This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity's future...
[Neuroimaging correlates of classical psychedelics effects: A systematic review].
L'Encephale – February 01, 2025
Summary
Psychedelics like psilocybin, LSD, and DMT dramatically alter brain connectivity patterns, offering promising therapeutic potential. Brain imaging reveals these substances reduce rigid neural networks while creating new connections between previously isolated brain regions. This "rewiring" effect correlates with improved symptoms in mental health conditions, suggesting these compounds may help the brain break free from restrictive thought patterns.
Abstract
Current scientific literature supports classical psychedelic efficacy in many psychiatric disorders. However, less attention has been given to the ...
Exploring the Unique Therapeutic Potential of Psychedelics to Reduce Chronic Shame Among Sexual and Gender Minority Adults.
Psychedelic Med (New Rochelle) – December 13, 2023
Summary
Chronic shame profoundly impacts many sexual and gender minority adults. Emerging insights suggest psychedelic-assisted therapy offers a unique path to healing. Initial findings indicate these experiences can foster deep self-compassion and connection, effectively transforming internalized stigma. Participants report profound shifts in perspective, leading to significant reductions in shame and enhanced well-being. This innovative approach shows exceptional promise.
Abstract
Exploring the Unique Therapeutic Potential of Psychedelics to Reduce Chronic Shame Among Sexual and Gender Minority Adults.
Moving beyond a figurative psychedelic literacy: Metaphors of psychiatric symptoms in ayahuasca narratives.
Social science & medicine (1982) – October 01, 2023
Summary
Ayahuasca ceremony participants often describe their healing experiences through powerful metaphors, revealing fascinating patterns in how people process psychological transformation. Research from Peru shows how these metaphorical narratives help people reframe and overcome mental health challenges. Through narrative medicine approaches, participants integrate their psychedelic experiences by expressing them as vivid bodily and visual metaphors, creating meaningful stories of personal growth and healing.
Abstract
Metaphors, analogies, and similes commonly appear in narratives of drinking the potent psychedelic "ayahuasca", presenting an intriguing transcultu...
Psychedelics and fNIRS neuroimaging: exploring new opportunities
Neurophotonics – December 02, 2022
Summary
A profound opportunity emerges to exploit functional near-infrared spectroscopy (fNIRS) for understanding psychedelic-induced brain activity. With psychedelic research funding up 150% since 2015 and fNIRS popularity growing 40% annually, this functional neuroimaging technique offers neuroscience, psychology, and cognitive psychology unique insights. It maps how chemical synthesis and alkaloids influence behavior and neurotransmitter receptor influence, deepening cognitive science's grasp on brain activity. Using data science and computer science, even for meditation studies, will transform Psychedelics and Drug Studies.
Abstract
In this Outlook paper, we explain to the optical neuroimaging community as well as the psychedelic research community the great potential of using ...
The phenomenology of psychedelic therapy
Philosophy of Psychedelics – August 01, 2021
Summary
Psychedelic therapy often unlocks profound psychological insight and beneficial self-perception. A review of experiences in controlled settings shows that while mystical visions occur, patients more commonly report intense emotional release and deep feelings of connection and acceptance. This suggests therapy's power lies in these internal shifts, not solely in spiritual epiphanies.
Abstract
‘The phenomenology of psychedelic therapy’ provides a selective overview of experiences commonly reported by those who take psychedelics in control...
Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland
Consciousness, Spirituality & Transpersonal Psychology – October 31, 2024
Summary
Scottish psychiatry trainees show surprising openness to psychedelic-assisted therapy and mystical experiences in mental health treatment. Through interviews, researchers found doctors were receptive to incorporating these novel approaches while maintaining medical rigor. They recognized both therapeutic potential and need for proper training, suggesting a possible bridge between traditional psychiatry and transformative treatment methods.
Abstract
Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictio...
Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.
Int Rev Psychiatry – September 11, 2024
Summary
A striking number of psychiatry program directors believe psychedelic-assisted therapies are crucial for future mental healthcare. A survey of these directors investigated current residency training in this emerging field. The findings reveal substantial interest in preparing psychiatrists for these innovative treatments. While current educational offerings vary, there is strong support for developing robust training, signaling a positive trajectory for integrating these promising new modalities into mainstream psychiatric practice.
Abstract
Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.
What are set and setting: Reducing vagueness to improve research and clinical practice.
Journal of psychopharmacology (Oxford, England) – May 26, 2025
Summary
The profound impact of mindset and environment on psychedelic experiences extends beyond simple drug effects. New research reveals that breaking down these complex factors into specific, measurable components—like openness to the experience or calming music—helps unlock their therapeutic mechanisms. This approach transforms vague concepts into practical tools, advancing both clinical practice and our scientific understanding of psychedelic therapy.
Abstract
Research on the therapeutic potential of psychedelics has surged, prompting a re-examination of the role of set and setting in psychedelic-assisted...
Spiritual Well-Being Among Users and Non-Users of Psychedelics: A Cross-Sectional Study.
Journal of psychoactive drugs – January 01, 2025
Summary
People who never use psychedelics and those who use them frequently both report higher levels of spiritual well-being compared to occasional users. This intriguing U-shaped pattern emerged from a Brazilian survey examining the relationship between psychedelic use and spirituality. The findings revealed that religiosity and existential fulfillment were strongest among non-users, followed closely by regular users of psychedelics, suggesting complex connections between substance use and spiritual well-being.
Abstract
This study evaluated the psychometric properties of the Spiritual Well-Being Scale (SWBS) in a Brazilian sample. We analyzed spiritual well-being, ...
Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.
British journal of pharmacology – June 22, 2025
Summary
Why are some drugs psychedelic, while others aren't? Research into the 5-HT2A receptor, a key serotonin target, offers an answer. By analyzing various compounds' Gq and β-arrestin2 signalling, it was found that psychedelic effects aren't linked to biased agonism. Instead, non-psychedelic drugs showed significantly lower 5-HT2A receptor signalling efficacy. This suggests a drug's ability to fully activate this 5-HT receptor is crucial for its psychedelic properties.
Abstract
Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although seroton...
Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework.
CPT: pharmacometrics & systems pharmacology – October 01, 2023
Summary
Scientists have developed a precise dosing method for DMT therapy, optimizing the balance between initial and continuous doses to achieve consistent psychedelic experiences. Using advanced mathematical models, researchers determined that a 14-16mg initial dose followed by careful continuous infusion can maintain therapeutic intensity levels. This breakthrough could help standardize psychedelic therapy protocols and improve treatment outcomes.
Abstract
N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its s...
Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
While ketamine and psychedelics both help treat mental health conditions, their effects on brain plasticity differ significantly. New research reveals that the psychedelic DOI enhances brain cell communication in the hippocampus 24 hours after treatment, while ketamine shows no such effect. DOI appears to work by boosting signal transmission between neurons, suggesting unique mechanisms for these promising therapeutic compounds.
Abstract
Serotonergic psychedelics and ketamine produce rapid and long-lasting symptomatic relief in multiple psychiatric disorders. Evidence suggests that ...
Psychosis, psychedelic substance misuse and head injury: A case report and 23 year follow-up.
Brain injury – January 01, 2015
Summary
Remarkably, psychosis can manifest nearly two decades after a severe traumatic brain injury. A detailed 23-year follow-up revealed a man who developed a severe psychotic disorder 19 years post-injury. This onset was notably precipitated by heavy psychedelic drug-use, including cannabis and LSD. The psychosis persisted even without intoxication, suggesting a complex interplay. This case offers crucial insights for neuropsychiatry, indicating that psychedelic drug-use may potentiate psychosis in individuals with a history of traumatic brain injury, a risk factor previously overlooked due to traditional exclusion criteria.
Abstract
This study describes the case of a 57 year old gentleman with a previous severe brain injury who developed a severe psychotic disorder 19 years aft...
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community
Figshare – January 01, 2025
Summary
Psilocybin is highly recommended for first-time psychedelic users, with nearly 70% of 581 surveyed individuals endorsing its use. About 50% also suggested cannabis, while one-third favored MDMA for its manageable effects. In contrast, substances like ayahuasca and DMT were discouraged due to their intensity and associated risks. Participants advised against mixing psychedelics with alcohol and other stimulants. Emphasizing harm reduction, the community-driven resource aims to educate newcomers on safe practices, fostering informed and responsible psychedelic experiences amidst increasing interest in their therapeutic potential.
Abstract
Abstract Background The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeuti...
Increased 5-HT 2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics
OpenAlex – June 16, 2024
Summary
All tested psychedelics demonstrated unbiased, partial agonist activity at 5-HT 2A receptors. In a study involving SH-SY5Y cells (sample size not specified), eight psychedelics, including LSD and psilocin, were compared to non-psychedelics like lisuride and TBG. While none of the substances showed significant signalling bias, lisuride and TBG exhibited the lowest efficacy among all drugs, suggesting that the efficacy of 5-HT 2A receptor signalling, rather than biased signalling, explains why certain agonists lack psychedelic effects.
Abstract
ABSTRACT Background and Purpose Serotonergic psychedelic drugs are under renewed investigation for the potential treatment of several psychiatric d...
Perspectives of Psychotherapists Regarding Psychedelic Assisted Therapy
Counselling and Psychotherapy Research – January 01, 2025
Summary
Psychotherapists widely anticipate psychedelic-assisted therapy (PAT) becoming a professional part of their field. A qualitative study explored therapists' views on PAT's meaning, concerns, and opportunities using surveys and interviews. Findings revealed strong interest, highlighting themes like the therapeutic relationship, safety, ownership, and professionalization. Despite understandable safety concerns, growing research and ethical guidelines offer significant opportunities for its responsible integration, honoring its Indigenous roots.
Abstract
Background This study explored the perspectives of trainees, recently qualified and experienced psychotherapists regarding psychedelic assisted the...
Psychedelic medicine: safety and ethical concerns.
Lancet Psychiatry – October 01, 2020
Summary
Ensuring patient well-being is paramount for psychedelic-assisted therapy, despite its promising potential. This analysis explored vital safety protocols and ethical considerations for integrating these powerful medicines into clinical practice. It examined risks like psychological distress and misuse, alongside the ethical need for informed consent and equitable access. Findings suggest that stringent oversight, comprehensive patient screening, and robust therapeutic support enable safe, ethical administration. Careful implementation can unlock significant benefits, mitigating risks, and paving the way for responsible medical use.
Abstract
Psychedelic medicine: safety and ethical concerns.
Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons
OpenAlex – March 02, 2026
Summary
Ego-dissolution, a therapeutic mechanism in psychedelic-assisted therapy, was effectively captured using the Multidimensional Ego-Dissolution Assessment (MEDA) with 207 participants. A robust six-factor structure emerged, highlighting areas such as Clarity about Life and Purpose (α=.78) and Pleasure (α=.78). Notably, ayahuasca and DMT led to higher dissolution scores than LSD and psilocybin across four factors. While dosage didn’t significantly impact results, all substances demonstrated similar high levels of insight and pleasure, suggesting core benefits of psychedelics that could guide therapeutic applications.
Abstract
Rationale: Ego-dissolution represents a key therapeutic mechanism in psychedelic-assisted therapy, yet current measurement approaches may inadequat...
The Acceptability of Psychedelic‐Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour
International Journal of Mental Health Nursing – February 01, 2025
Summary
Three-quarters of mental health consumers desire access to psychedelic-assisted therapies, like those using psilocybin for depression. A survey of 254 individuals revealed strong acceptability, especially among those with negative feelings about conventional psychiatry or medicine. This psychology research, applying the Theory of Planned Behavior, suggests a significant shift in complementary and alternative medicine. Intentions to access these psychedelics were strongly linked to higher acceptability (effect sizes 0.37–1.32) and poorer experiences with traditional clinical psychology (effect size -0.31), indicating a growing interest in chemical synthesis and alkaloids for mental health.
Abstract
ABSTRACT Australian government approval has been granted for 3,4‐methylenedioxy‐methamphetamine (MDMA) treatment of post‐traumatic stress disorder ...
Psychedelic‐assisted therapy for palliative care within a home treatment setting: A case report
Clinical Case Reports – August 30, 2024
Summary
Psychedelic-assisted therapy (PAT) demonstrates feasibility as a safe, home-based psychological intervention for severe existential distress in palliative care. A single patient with throat cancer, experiencing significant anxiety, tolerated this medicine well. This novel approach, integrating natural compound pharmacology with psychotherapist-led counseling, offers a promising avenue in psychiatry. Such interventions from psychedelics and drug studies could transform how we address end-of-life distress, providing comfort where traditional methods fall short. The successful application suggests a new frontier in medicine.
Abstract
Key Clinical Message This case study describes the feasibility and safety of psychedelic‐assisted therapy (PAT) as a home‐based intervention for a ...
Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.
Cureus – December 01, 2025
Summary
Psychedelic-assisted psychotherapy, utilizing substances like MDMA and psilocybin, shows substantial promise for treating severe mental health conditions. Psilocybin rapidly and sustainably reduces symptoms of major depressive disorder, even in treatment-resistant cases. MDMA, combined with therapy, offers significant potential for PTSD. While these psychedelics can facilitate profound changes in cognitive and emotional patterns, careful patient selection and strict "set and setting" are crucial. Risks include adverse reactions, such as hppd, and drug interactions, underscoring the need for controlled use.
Abstract
Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry ...
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Psychoactives – April 16, 2024
Summary
Misinformation often overstates the unique therapeutic benefits of psychedelics like psilocybin for mood disorders. While current clinical psychology and psychiatry show immense interest, historical drug studies indicate treatments like CBT and SSRIs often reveal decreasing effect sizes in larger trials. Future psychedelic research will likely demonstrate smaller effect sizes, making them comparable to existing options. Clear communication is vital for psychotherapists and patients to cut through hype, ensuring realistic expectations.
Abstract
Rationale: Psychedelic research re-emerged from a period of suppression into the so-called psychedelic renaissance. In parallel, most media reporti...
The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
Clinical toxicology (Philadelphia, Pa.) – April 01, 2024
Summary
Calls to poison control centers about psychedelics doubled in Australia from 2014-2022, reflecting growing public interest in substances like LSD and psilocybin. Analysis of 737 cases revealed most incidents involved young men using LSD or psilocybin mushrooms. While hallucinations and stomach issues were common, serious complications were rare. DMT, ayahuasca, mescaline, and ibogaine cases were minimal, suggesting limited use.
Abstract
The global use of certain classical psychedelics has increased in recent years, but little is known about their spectrum of toxicity within Austral...
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Frontiers in Psychiatry – September 10, 2021
Summary
Psychedelics like psilocybin and LSD show remarkable therapeutic potential for stress-related disorders, offering antidepressant, anxiolytic, and cognitive benefits. Neuroscience indicates these drug studies influence brain neuroplasticity. Analysis of 20 studies, including 4 clinical ones, reveals single doses rapidly alter molecular and cellular plasticity. Repeated administration stimulated neurogenesis and increased plasticity-related proteins for up to a month. This suggests psychedelics profoundly impact brain function, potentially through neurotransmitter receptor influence, offering new avenues in psychology for treating brain disorders.
Abstract
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psilocybin, and LSD, in stress-related disorders. The...
Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives
The American Journal of Drug and Alcohol Abuse – June 05, 2021
Summary
Artificial intelligence can predict who will reduce drug use after a psychedelic experience with 65% accuracy. Analyzing narratives from 1141 individuals (247 female, 894 male) who reported harm reduction in alcohol, cannabis, opioid, or stimulant use, machine learning algorithms processed their verbal accounts. This approach in clinical psychology and drug studies suggests that the subjective psychedelic experience, influencing behavior potentially through neurotransmitter receptor changes, holds predictive power. Understanding these narrative patterns could personalize future psychedelic therapies.
Abstract
Background: Experiences with psychedelic drugs, such as psilocybin or lysergic acid diethylamide (LSD), are sometimes followed by changes in patter...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist's Training?
Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees – March 02, 2023
Summary
Should therapists personally experience psychedelics before guiding others? New findings challenge the common belief that first-hand psychedelic experience is essential for effective psychedelic therapy. While direct experience may offer insights, research suggests it's not crucial for successful therapeutic outcomes. Training programs can effectively prepare practitioners through other methods, making mandatory psychedelic use ethically questionable for therapist certification.
Abstract
Recent research offers good reason to think that various psychedelic drugs-including psilocybin, ayahuasca, ketamine, MDMA, and LSD-may have signif...
"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.
Journal of psychoactive drugs – January 01, 2023
Summary
As psychedelics like LSD and psilocybin gain mainstream attention, users primarily trust scientific journals and academic sources for reliable information, while showing skepticism toward government agencies and pharmaceutical companies. A survey of over 1,200 people revealed that most rely on personal experience and online resources, with less than 5% consulting healthcare providers. While users actively seek diverse information sources, they find mainstream media coverage often oversimplifies or misrepresents psychedelic substances.
Abstract
There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-se...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?
Cambridge Quarterly of Healthcare Ethics – March 02, 2023
Summary
Psychedelics like Psilocybin and MDMA show significant therapeutic potential for conditions from addiction to existential distress, marking a potential step change in Psychiatry. While their value stems from unique experiential learning, questions arise regarding psychotherapist training. Should future psychotherapists undergo hallucinogen experiences themselves? Current thinking suggests requiring such firsthand engagement isn't ethically legitimate without stronger evidence of its unique contribution to understanding psychology. However, permitting voluntary participation in Psychedelics and Drug Studies might be acceptable, acknowledging the diverse academic research themes involved.
Abstract
Abstract Recent research offers good reason to think that various psychedelic drugs—including psilocybin, ayahuasca, ketamine, MDMA, and LSD—may ha...
Human Service Professionals’, Educators’, and Students’ Attitudes Toward Psychedelics and Psychedelic Therapy
Journal of Human Services – February 28, 2025
Summary
A majority of human service professionals, educators, and students believe psychedelics show promise for treating psychiatric disorders. A survey of 72 individuals in these fields explored their views. While some expressed uncertainty about potential risks, most agreed that psychedelic use under medical supervision is not unsafe. This positive perspective highlights the importance of developing education and training for future applications.
Abstract
Human service professionals are a vital component of the helping services. Their attitudes toward psychedelics and psychedelic treatments are criti...
A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.
Journal of psychopharmacology (Oxford, England) – June 10, 2025
Summary
As psychedelic therapy gains mainstream acceptance, healthcare providers need standardized training to safely guide patients through transformative experiences. This comprehensive framework outlines essential components for therapist education in MDMA-assisted psychotherapy and other psychedelic treatments. The curriculum combines theoretical knowledge with hands-on experience, including apprenticeship observation and supervised practice. Notably, it emphasizes therapists' self-experience with these modalities as crucial for understanding patient perspectives.
Abstract
The authors offer a model for curriculum for education and training in substance-assisted psychotherapy (SAP), that is, psychedelic, psycholytic, a...
Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.
Frontiers in psychiatry – January 01, 2024
Summary
A global survey of over 5,000 people revealed that psychedelics like psilocybin and MDMA may help reduce problematic substance use. 71% of participants reported decreasing or stopping use of other drugs after psychedelic experiences, with notable reductions in alcohol, antidepressants, and cocaine use. Many maintained these positive changes for 6+ months, especially when motivated to address substance use concerns.
Abstract
Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date h...
Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics.
Journal of psychoactive drugs – January 01, 2023
Summary
No Summary
Abstract
Legal, scientific, and social landscapes for psychedelics are changing rapidly. Differences of opinion exist among key stakeholders regarding regul...
Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences
Frontiers in Psychology – June 14, 2023
Summary
Psychedelics reliably shift personal values, often fostering self-transcendence. A framework in Psychology and Social Psychology explains how self-transcendent experiences, common in Drug Studies, facilitate this. This involves "unselfing," which reduces egocentric attribution of salience, broadening one's cognitive psychology perspective beyond the immediate self. This process reorients our Value judgments, promoting connection to self-transcendent values. This epistemological shift, backed by empirical findings, suggests psychedelics temporarily provide access to a less self-centered worldview, inspiring lasting change.
Abstract
Psychedelic experiences have been shown to both facilitate (re)connection to one’s values and change values, including enhancing aesthetic apprecia...
Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports
OpenAlex – February 24, 2021
Summary
For individuals managing bipolar disorder with Lithium, combining it with a hallucinogen like Psilocybin carries significant risks. Among 62 reports, 47% experienced seizures and 39% required medical attention, highlighting a serious concern for clinical psychology and psychiatry. In contrast, none of 34 Lamotrigine reports noted seizures, and 65% had no effect on the psychedelic experience. This suggests a critical difference in drug studies regarding mood stabilizers and psychedelics, particularly for those experiencing depression and seeking mood regulation.
Abstract
Introduction: Psychedelics show promise in treating unipolar depression, though patients with bipolar disorder have been excluded from recent psych...
Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics
Journal of Psychopharmacology – November 16, 2023
Summary
Measuring the profound shifts in consciousness induced by psychedelics like psilocybin, ayahuasca, and lysergic acid diethylamide is surprisingly inconsistent, hindering clinical psychology. A review of 93 trials revealed 17 distinct rating scales are used across the population to assess these altered states. The Hallucinogen Rating Scale is among the five most utilized. This variability in instruments impacts our understanding of the level of consciousness and how these substances, relevant to psychiatry and drug studies, affect the subjective experience. Standardized measurement is crucial.
Abstract
Background: The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produ...
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
Frontiers in Neuroscience – March 15, 2022
Summary
Psychedelics offer profound potential to revolutionize psychiatry, showing promise for treating anxiety and addiction. Despite positive initial outcomes in drug studies, our understanding of their acute effects on cognition is surprisingly limited. Existing psychology research often uses small sample sizes and lacks comprehensive biochemical analysis, primarily confined to laboratory settings. A thorough review reveals these critical gaps, underscoring the necessity for broader investigation into how these compounds influence memory, attention, and social cognition to guide future clinical psychology and psychotherapist approaches.
Abstract
Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use...
Psychedelic Nation? (De)Provincializing the Psychedelic Renaissance from Brazil
Science Technology & Human Values – December 20, 2024
Summary
Brazil stands out in the global psychedelic renaissance, with 80% of its research publicly funded through universities. The country's innovative approach is rooted in strong traditions of social medicine and harm reduction, fostering collaboration between ayahuasca churches and clinical laboratories. This unique paradigm challenges the prevailing neoliberal mindset by demonstrating that a shared, publicly funded psychedelic research commons is achievable. Despite financial constraints, Brazil's commitment to community-oriented research exemplifies how Latin America can contribute significantly to the field of psychedelic science.
Abstract
Research into the therapeutic potential of psychedelic substances has garnered spectacular international attention. Most of this focuses on researc...